Trastuzumab Rezetecan versus Trastuzumab Deruxtecan for unresectable HER2‑low, HR‑positive breast cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 2 interventional trial enrolls women aged 18–75 with HR-positive, HER2-low unresectable locally recurrent or metastatic breast cancer who progressed after endocrine therapy and have not received chemotherapy for metastatic disease. Participants receive injections of Trastuzumab Rezetecan at different dose levels or Trastuzumab Deruxtecan, with monitoring for tumor response and safety using RECIST v1.1 and standard clinical assessments. The protocol also includes exploratory pharmacokinetic and immunogenicity sampling to characterize drug levels and anti-drug antibodies. The trial is sponsored by Jiangsu HengRui Medicine and conducted at the Cancer Hospital, Chinese Academy of Medical Sciences in Beijing.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Female aged 18 to 75 years (inclusive).
2. Unresectable locally recurrent or metastatic breast cancer.
3. Prior therapy must meet the following: No prior chemotherapy for recurrent/metastatic disease. Must have received at least one prior line of endocrine therapy for recurrent/metastatic disease with disease progression, and the investigator judges that further benefit from endocrine therapy is not possible.
4. Documented radiological disease progression (during or after the most recent therapy).
5. ECOG performance status of 0 or 1.
6. Life expectancy ≥ 12 weeks.
7. At least one extracranial measurable lesion as a target lesion according to RECIST v1.1 criteria.
8. Adequate function of major organs.
9. Pregnancy and contraception: Women of childbearing potential (WOCBP) must agree to use highly effective contraception from study screening until 7 months after the last dose of study drug and agree not to breastfeed; serum pregnancy test result must be negative within 7 days before the first dose.
10. The patient voluntarily participates in this study, signs the informed consent form, has good compliance, and is willing to cooperate with visits and study-related procedures.

Exclusion Criteria:

1. Presence of leptomeningeal metastasis/carcinomatous meningitis, spinal cord compression, or active central nervous system metastases.
2. Patients with only skin or brain lesions as target lesions.
3. History of other malignancies within the past 5 years, except for cured basal cell carcinoma of the skin or carcinoma in situ of the cervix.
4. Presence of carcinomatous lymphangitis, or third-space fluid accumulation that cannot be controlled by methods such as drainage.
5. Prior surgery, chemotherapy, immunotherapy, or macromolecular targeted therapy within 4 weeks before the first dose; prior endocrine therapy, chemotherapy with 5-FU analogs, or radiotherapy within 2 weeks before the first dose; small molecule targeted agents require a washout period of 2 weeks or 5 half-lives; other investigational drugs require a washout period of 4 weeks or 5 half-lives before the first dose.
6. Use of immunosuppressants or systemic corticosteroids for immunosuppressive purposes within 2 weeks before the first dose for therapeutic intent.
7. History of immunodeficiency, including a positive HIV test, other acquired or congenital immunodeficiency diseases, or history of organ transplantation.
8. Clinically significant cardiovascular disease, such as severe/unstable angina, symptomatic congestive heart failure, etc.; clinically significant supraventricular or ventricular arrhythmia requiring treatment or intervention; myocardial infarction or cerebrovascular accident within 6 months before the first dose.
9. Participants with known or suspected interstitial lung disease; other moderate-to-severe pulmonary diseases that may interfere with the detection or management of drug-related pulmonary toxicity and severely affect respiratory function within 3 months before the first dose; and any autoimmune, connective tissue, or inflammatory disorders with pulmonary involvement.
10. Known hereditary or acquired bleeding tendency.
11. Active hepatitis B, hepatitis C, or cirrhosis; or severe infection requiring control with antibiotics, antivirals, or antifungals.
12. Toxicities from prior anti-tumor therapy have not recovered to ≤ Grade 1 (according to NCI-CTCAE v5.0).
13. Any other severe physical or mental illness or laboratory abnormality that may increase the risk associated with study participation, interfere with study results, or any other condition for which the investigator considers the patient unsuitable for participation in this study.

Where it's running

• Cancer Hospital, Chinese Academy of Medical Sciences
  Beijing, Beijing Municipality, China Recruiting

Study contacts

• Study coordinator: Xia Zhang
• Email: xia.zhang@hengrui.com
• Phone: +86-0518-82342973

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Neoadjuvant trastuzumab, durvalumab, and FLOT for HER2-positive gastric or GEJ cancer

  This study tests a pre-surgery treatment combining trastuzumab, durvalumab, and FLOT for patients with HER2-positive locally advanced gastric or gastroesophageal junction cancer to see how many achieve complete tumor disappearance.

  Recruiting Phase 2 Samsung Medical Center · Seoul, Gang-Nam · NCT07911280

• Neoadjuvant Pyrotinib-to-pertuzumab for HER2-positive early breast cancer

  This trial tests whether a two-step neoadjuvant plan with Pyrotinib plus Trastuzumab and Docetaxel followed by Pertuzumab plus Trastuzumab and Docetaxel works better than four cycles of Pertuzumab plus Trastuzumab and Docetaxel in women with HER2-positive early- to locally advanced breast cancer.

  Recruiting Phase 3 Shanghai Jiao Tong University School of Medicine · Shanghai · NCT07797218

• Trastuzumab Rezetecan and Gemcitabine before surgery for HER2-positive UTUC

  This study tests whether giving trastuzumab deruxtecan with gemcitabine before and around surgery can improve outcomes for people with HER2-positive upper tract urothelial cancer.

  Recruiting at 10 sites Phase 2 Tongji Hospital · Huanggang, Hubei and 9 other locations · NCT07741448

• Foslorapitant with Palonosetron to Help Prevent Nausea and Vomiting from Trastuzumab Rezetecan

  A single-arm study tests whether giving foslorapitant plus palonosetron can prevent chemotherapy-induced nausea and vomiting in adults receiving Trastuzumab Rezetecan.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin · NCT07726433

• Auricular point stimulation with dexamethasone versus standard antiemetics for nausea from trastuzumab deruxtecan

  This trial tests whether adding ear acupuncture-style stimulation to dexamethasone can prevent and reduce nausea and vomiting caused by trastuzumab deruxtecan in breast cancer patients, compared with the usual antiemetic regimen.

  Recruiting Phase 3 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou · NCT07716189

• Entinostat with Pyrotinib and Endocrine Therapy in HER2-positive, HR-positive Advanced Breast Cancer after Trastuzumab Failure

  This study tests whether adding entinostat to pyrotinib and hormone therapy is safe and helps patients with advanced HR+/HER2+ breast cancer who progressed after trastuzumab.

  Recruiting Phase 1/2 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT07708194

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.